New oral anticoagulants and chronic kidney disease;Neue orale Antikoagulanzien und Niereninsuffizienz

Internist

Volumn 53, Issue 12, 2012, Pages 1431-1444

  Bauersachs, R M ^a  

^a KLINIKUM DARMSTADT   (Germany)

Author keywords

Apixaban; Atrial fibrillation; Dabigatran; Rivaroxaban; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DRUG ACCUMULATION; DRUG EFFICACY; DRUG EXCRETION; HEART ATRIUM FIBRILLATION; HUMAN; PREVALENCE; RISK FACTOR; URINARY EXCRETION; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; CLASSIFICATION;

ANTICOAGULANTS; HEMORRHAGE; HUMANS; RENAL INSUFFICIENCY, CHRONIC; VENOUS THROMBOEMBOLISM;

EID: 84877038201     PISSN: 00209554     EISSN: 14321289     Source Type: Journal    
DOI: 10.1007/s00108-012-3146-y     Document Type: Article

References (43)

1. (o A) (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:1-266
2. Atar I, Konas D, Acikel S, et al. (2006) Frequency of atrial fibrillation and factors related to its development in dialysis patients. Int J Cardiol 106:47-51
3. Bauersachs R, Berkowitz SD, Brenner B, et al. (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499-2510
4. Bauersachs RM (2012) Use of anticoagulants in elderly patients. Thromb Res 129:107-115
5. Bauersachs RM, Gogarten W, Hach-Wunderle V, et al. (2012) Perioperatives Management der Antikoagulation mit Rivaroxaban. Klinikarzt 41:418-425
6. Camm AJ, Kirchhof P, Lip GY, et al. (2010) Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369-2429
7. Camm AJ, Kirchhof P, Lip GY, et al. (2010) Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Europace 12:1360-1420
8. Connolly SJ, Eikelboom J, Joyner C, et al. (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364:806-817
9. Connolly SJ, Ezekowitz MD, Yusuf S, et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151
10. Coresh J, Selvin E, Stevens LA, et al. (2007) Prevalence of chronic kidney disease in the United States. JAMA 298:2038-2047
11. Eikelboom JW, Connolly SJ, Gao P, et al. (2012) Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis 21:429-435
12. Gage BF, Yan Y, Milligan PE, et al. (2006) Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 151:713-719
13. Gangireddy C, Rectenwald JR, Upchurch GR, et al. (2007) Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg 45:335-341
14. Go AS, Fang MC, Udaltsova N, et al. (2009) Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 119:1363-1369
15. Granger CB, Alexander JH, McMurray JJ, et al. (2012) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981-992
16. Harder S (2012) Renal profiles of anticoagulants. J Clin Pharmacol 52:964-975
17. Hariharan S, Madabushi R (2012) Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol 52:119-125
18. Harper P, Young L, Merriman E (2012) Bleeding risk with dabigatran in the frail elderly. N Engl J Med 366:864-866
19. Hart RG, Eikelboom JW, Ingram AJ, Herzog CA (2012) Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol 8:569-578
20. Lee M, Saver JL, Chang KH, et al. (2010) Low glomerular filtration rate and risk of stroke: meta-analysis. BMJ 341:c4249
21. Lehr T, Haertter S, Liesenfeld KH, et al. (2011) Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol 52:1373-1378
22. Lim W (2010) Using low molecular weight heparin in special patient populations. J Thromb Thrombolysis 29:233-240
23. Lip GY, Frison L, Halperin JL, Lane DA (2011) Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 57:173-180
24. Mack DR, Kim JJ (2012) Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation. Ann Pharmacother 46:1105-1110
25. Marinigh R, Lane DA, Lip GY (2010) Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 57:1339-1348
26. Marinigh R, Lip GY, Fiotti N, et al. (2010) Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol 56:827-837
27. Miyasaka Y, Barnes ME, Gersh BJ, et al. (2006) Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980-2000, and implications on the projections for future prevalence. Circulation 114:119-125
28. Monreal M, Falga C, Valle R, et al. (2006) Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 119:1073-1079
29. Olesen JB, Lip GY, Kamper AL, et al. (2012) Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 367:625-635
30. Patel MR, Mahaffey KW, Garg J, et al. (2011) Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 365:883-891
31. Poulsen BK, Grove EL, Husted SE (2012) New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs 72:1739-1753
32. Reinecke H, Brand E, Mesters R, et al. (2009) Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 20:705-711
33. Ruiz-Gimenez N, Suarez C, Gonzalez R, et al. (2008) Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 100:26-31
34. Schulman S, Kakkar A, Schellong S, et al. (2011) A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood 118:Abstract 205. American Society of Hematology 2011 Annual Meeting, San Diego/CA
35. Schulman S, Kearon C, Kakkar AK, et al. (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342-2352
36. Silverstein MD, Heit JA, Mohr DN, et al. (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158:585-593
37. Soliman EZ, Prineas RJ, Go AS, et al. (2010) Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 159:1102-1107
38. Spannagl M, Bauersachs R, Debus ES, et al. (2012) Patienten unter Therapie mit Dabigatran: Periinterventionelles Management. Hamostaseologie 32 (im Druck)
39. The Einstein Investigators, Buller HR, Prins MH, et al. (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287-1297
40. US Renal Data System, National Institutes of Health (2012) USRDS 2012 Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda/MD
41. Wizemann V, Tong L, Satayathum S, et al. (2010) Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 77:1098-1106
42. Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:983-988
43. Yang F, Chou D, Schweitzer P, Hanon S (2010) Warfarin in haemodialysis patients with atrial fibrillation: what benefit? Europace 12:1666-1672